Skip to main content

Heart Viability

  • Chapter
PET-CT
  • 892 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bergmann SR. Use and limitations of metabolic tracers labeled with positron-emitting radionuclides in the identification of viable myocardium. J Nucl Med 1994;35(4 Suppl):15S–22S.

    PubMed  Google Scholar 

  2. Brink I, Nitzsche EU, Mix M, et al. Appropriate uptake period for myocardial PET imaging with 18F-FDG after oral glucose loading. Nuklearmedizin. 2003;42(1):39–44.

    PubMed  Google Scholar 

  3. Grandin C, Wijns W, Melin JA, et al. Delineation of myocardial viability with PET. J Nucl Med 1995;36(9):1543–1552.

    PubMed  Google Scholar 

  4. Maddahi J. Cardiovascular nuclear medicine: state-of-the-art. J Nucl Med 1994;35(4):672–673.

    PubMed  Google Scholar 

  5. Schelbert HR, Beanlands R, Bengel F, et al. PET myocardial perfusion and glucose metabolism imaging: Part 2-guidelines for interpretation and reporting. J Nucl Cardiol 2003;10:557–571.

    Article  PubMed  Google Scholar 

  6. Schelbert HR. Metabolic imaging to assess myocardial viability. J Nucl Med 1994;35(4 Suppl):8S–14S.

    PubMed  Google Scholar 

  7. Schinkel AFL, Bax JJ, van Domburg R, et al. Dobutamine-induced contractile reserve in stunned, hibernating, and scarred myocardium in patients with ischemic cardiomyopathy. J Nucl Med 2003;44:127–133.

    PubMed  Google Scholar 

  8. Schinkel AFL, Bax JJ, Valkema R, et al. Effect of diabetes mellitus on myocardial 18F-FDG SPECT using acipimox for the assessment of myocardial viability. J Nucl Med 2003;44:877–883.

    PubMed  Google Scholar 

  9. Tamaki N, Morita K, Kuge Y, Tsukamoto E. The role of fatty acids in cardiac imaging. J Nucl Med 2000;41:1525–1534.

    PubMed  Google Scholar 

  10. Vitale GD, deKempe RA, Ruddy TD, Williams K, Beanlands RS. Myocardial glucose utilization and optimization of 18F-FDG imaging in patients with non-insulin-dependent diabetes mellitus, coronary artery disease, and left ventricular dysfunction. J Nucl Med 2001;42:1730–1736.

    PubMed  Google Scholar 

  11. Zhang X, et al. Clinical outcome of patients with previous myocardial infarction and left ventricular dysfunction assessed with myocardial 99mTc-MIBI SPECT and 18F-FDG PET. J Nucl Med 2001;42:1166–1173.

    PubMed  Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Ramanna, L. (2005). Heart Viability. In: Conti, P.S., Cham, D.K. (eds) PET-CT. Springer, New York, NY. https://doi.org/10.1007/0-387-27044-2_13

Download citation

  • DOI: https://doi.org/10.1007/0-387-27044-2_13

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-20858-9

  • Online ISBN: 978-0-387-27044-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics